Devalued and Distrusted: Can the Pharmaceutical Industry Restore its Broken Image?

Devalued and Distrusted: Can the Pharmaceutical Industry Restore its Broken Image?

Volumn , Issue , 2013, Pages

  Lamattina, John L ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84891585128     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118511329     Document Type: Book

References (103)

1. Stipp, D. (2006) Take two possibly lethal pills and call me in the morning. Fortune, February 20.
2. Singer, N. (2011) Ingredients of shady origins, posing as supplements. New York Times, August 27.
3. De Kosky, S. T., Williamson, J. D., Fitzpatrick, A. L., Kronmal, R. A., Ives, D. G., Saxton, J. A., Lopez, O. L., Burke, G., Carlson, M. C., Fried, L. P., Kuller, L. H., Robbins, J. A., Tracy, R. P., Woolard, N. F., Dunn, L., Snitz, B. E., Nahin, R. L., Furberg, C. D. (2008) Ginkgo biloba for prevention of dementia: A randomized controlled trial. Journal of the American Medical Association, 300, 2253-2262.
4. Bent, S., Kane, C., Shinohara, K., Neuhaus, J., Hudes, E. S., Goldberg, D. O., Avins, A. L. (2006) Saw palmetto for benign prostatic hyperplasia. New England Journal of Medicine, 354, 557-566.
5. Barry, M. J., Meleth, S., Lee, J. Y., Kreder, K. J., Avins, A. L., Nickel, J. C., Roehrborn, C. G., Crawford, E. D., Foster, H. E., Kaplan, S. A., McCullough, A., Andriole, G. L., Naslund, M. J., Williams, O. D., Kusek, J. W., Myers, C. M., Betz, J. M., Cantor, A., McVary, K. T. (2011) Effects of increasing doses of saw palmetto extract on lower urinary tract symptoms; A randomized trial. Journal of the American Medical Association, 306, 1344-1351.
6. West, R., Zatonski, W., Cedeynska, M., Lewandoska, D., Pazik, J., Aveyard, P., Stapleton, J. (2011) Placebo-controlled trial of cytisine for smoking cessation. New England Journal of Medicine, 365, 1193-1200.
7. Jorenby, D. E., Hays, J. T., Rigotti, N. A., Azoulay, S., Watsky, E. J., Williams, K. E., Billing, C. B., Gong, J., Reeves, K. R. (2006) Efficacy of varenicline, an α4β2 nicotine acetylcholine receptor partial agonist, vs. placebo or sustained-release bupropion for smoking cessation. A randomized controlled trial. Journal of the American Medical Association, 296, 56-63.
8. Etter, J. F. (2009) Cytisine for smoking cessation. A literature review and a meta-analysis. Archives of Internal Medicine, 166, 1553-1559.
9. Mann, J. J. (2005) The medical management of depression. New England Journal of Medicine, 353, 1819-1834.
10. Walsh, B. T., Seidman, S. N., Sysko, R., Gould, M. (2002) Placebo response in studies of major depression. Journal of the American Medical Association, 287, 1840-1847.
11. Wang, S. S. (2012) Why placebos work wonders. From weight loss to fertility, new legitimacy for "fake" treatments. Wall Street Journal, January 3.
12. Prayle, A. P., Hurley, M. N., Smith, A. R. (2012) Compliance with mandatory reporting of clinical trial results on ClinicalTrials.gov: Cross sectional study. British Medical Journal, 344, d7373.
13. Ross., J. S., Tse, T., Zarin, D. A., Zhou, L., Kaumholz, H. M. (2012) Publication of NIH funded trials registered in ClinicalTrials.gov: Cross sectional analysis. British Medical Journal, 344, d7292.
14. Appel, L. J., Clark. J. M., Yeh, H-C., Wang, N. Y., Coughlin, J. W., Drum, T. G., Miller, E. R., Dalcin, A., Jerome, G. I., Geller, S., Noronha, G., Pozefsky, T., Charleston, J., Reynolds, J. B., Durkin, N., Rubin, R. R., Louis, T. A., Brancati, F. L. (2011) Comparative effectiveness of weight-loss interventions in clinical practice. New England Journal of Medicine, 365, 1959-1968.
15. Wadden, T. A., Volger, S., Sariner, D. B., Vetter, M. L., Tsai, A. G., Berkowitz, R. I., Kumanyika, S., Schmitz, K., Diewald, L. K., Barg, R., Chittams, J., Moore, R. H. (2011) A two-year randomized trial of obesity treatment in primary care practice. New England Journal of Medicine, 365, 1969-1979.
16. Berry, J. D., Dyer, A., Cai, X., Garside, D. B., Ning, H., Thomas, A., Greenland, P., VanHorn, L., Tracy, R. P., Lloyd-Jones, D. M. (2012) Lifetime risks of cardiovascular disease. New England Journal of Medicine 366, 321-330.
17. Heart Protection Study Collaborative Group (2001) Effects of 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20,536 high-risk individuals: A randomized controlled trial. The Lancet, 378, 2013-2020.
18. The AIM-HIGH Investigators (2011) Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. New England Journal of Medicine, 365, 2255-2267.
19. Moynihan, R., Heath, I., Henry, D. (2002) Selling sickness: The pharmaceutical industry and disease mongering. British Medical Journal, 324, 886-891.
20. Brody, J. (2011) A reminder on maintaining bone health. New York Times, November 1.
21. Lenzer, R. (2011) Disease creep: How we're fooled into using more medicine than we need. Available at www.newamerica.net/node/61818.
22. Miller, G. (2010) Is Pharma running out of brainy ideas? Science, 329, 502-504.
23. Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Linborg, S. R., and Schacht, A. L. (2010) How to improve R&D productivity: The pharmaceutical industry's grand challenge. Nature Reviews Drug Discovery, 9, 203-214.
24. Schmid, E. F., Smith, D. A. (2005) Is declining innovation in the pharmaceutical industry a myth? Drug Discovery Today, 10, 1031-1039.
25. Loftus, P. (2010) Merck to Shutter 16 Facilities. Wall Street Journal, July 9.
26. Herper, M. (2011) Peering Into Pfizer's Future. Forbes, April 10.
27. Pierson, R. (2011) Pfizer trims 2012 sales view, cuts R&D spending. Reuters, February 1.
28. Waters, R. (2010) Shrinking U.S. biotech sector lost 25% of companies in past 3 years. Bloomberg, October 5.
29. Armstrong, R. (2009) Biotech will save Big Pharma. Dow Jones Newswire, May 9. Data generated by Dr. John Arrowsmith at Thomson Reuters indicate that industry average for 2005-2009 for Phase 2 dwell times is 2.8 years (private communication).
30. Arnst, C. (2009) Drug mergers: Killers for research. Business Week, March 9.
31. LaMattina, J. L. (2011) The impact of mergers on pharmaceutical R&D. Nature Reviews Drug Discovery, 10, 1-2.
32. Firestone, R. A. (2011) Lessons from 54 years of research. Nature Reviews Drug Discovery, 10, 93.
33. Howard, L. (2010) These days, finding a new job means finding a new career. The Day, June 13.
34. Reid, K., Berkrot, B. (2010) Glaxo sees more industry consolidation. Reuters, November 10.
35. Rockoff, J. D. (2011) Pfizer, Merck take different R&D tacks. Wall Street Journal, February 4.
36. Stovall, S. (2011) R&D cuts curb brain-drug pipeline. Wall Street Journal, March 28.
37. Carpenter, D. (2010) Reputation and Power: Organizational Image and Pharmaceutical Regulation at the FDA. Princeton University Press, Princeton, NJ.
38. Hamburg, M. A. (2011) America's innovation agency: The FDA. Wall Street Journal, August 1.
39. Yukhananov, A. (2012) Drug lobby wants clearer FDA rules for diet pills. Reuters, January 20.
40. Calabresi, M. (2010) After Avandia, does the FDA have a drug problem? Time, August 12.
41. Bolden, M., Swamidass, S. J. (2011) A new bargain for drug approvals. Wall Street Journal, July 25.
42. Shimamura, T., Shiroshi, M., Weyland, S., Tsujimoto, H., Winter, G., Katritch, V., Abagyan, R., Cherezov, V., Liu, W., Han, G. W., Kobayashi, T., Stevens, R. C., Iwata, S. (2011) Structure of the human histamine H1 receptor complex with doxepin. Nature, 475, 65-70.
43. Krauskopf, L (2011) Pharma asks the money question earlier for new drugs. Reuters, December 20.
44. Herper, M. (2011) ALTITUDE Study of Aliskiren terminated early by Novartis. Forbes, December 20.
45. AVEO Press Release (2012) AVEO and Astellas announce tivozanib successfully demonstrated progression-free survival over sorafenib in patients with advanced renal cell cancer in phase 3 TIVO-1 trial. January 3.
46. Schmidt, C. (2011) Debate re-ignites contribution of public research to drug development. Nature Biotechnology, 29, 469-470.
47. Stevens, A. J., Jenson, J. J., Wyller, K., Kilgore, P. C., Chatterjee, S., Rohrbaugh, M. L. (2011) The role of public-sector research in the discovery of drugs and vaccines. New England Journal of Medicine, 364, 535-541.
48. Davis, P. B. (2011) Therapy for cystic fibrosis-The end of the beginning. New England Journal of Medicine, 365, 1734-1735.
49. Boseley, S. (2011) Cancer research in "golden era," says charity chief. Guardian.CO.UK, August 22.
50. Hallberg, B., Palmer, R. H. (2011) Crizotinib-Latest champion in the cancer wars. New England Journal of Medicine, 363, 1760-1762.
51. Eisenberg, C. (2011) NIH budget cuts may slow personalized cancer drugs, group says. Bloomberg, September 20.
52. Nelson, R. (2010) "War on cancer" more successful than perceived. Medscape Oncology, March 11.
53. Wang., S. S. (2011) Psychiatric drug use spreads. Wall Street Journal, November 16.
54. Mann, J. J. (2005) The medical management of depression. New England Journal of Medicine, 353, 1819-1834.
55. Kramer, P. D. (2011) In defense of antidepressants. New York Times, July 9. On August 6, 2012, Pfizer and J&J announced discontinuation of the bapineuzumab (intravenous) clinical trials due to lack of efficacy.
56. Berkrot, B. (2012) Pfizer, J&J scrap Alzheimer's studies as drug fails. Reuters, August 7.
57. Belluck, P. (2011) Grasping for any way to prevent Alzheimer's. New York Times, July 20.
58. Peterson, E. D., Gaziano, J. M. (2011) Cardiology in 2011-Amazing opportunities, huge challenges. Journal of the American Medical Association, 306, 2156-2157.
59. Steinberg, D., Witztum, J. (2009) Inhibition of PCSK9: A powerful weapon for achieving ideal LDL cholesterol levels. Proceedings of the National Academy of Sciences, 106, 9546-9547.
60. Langreth, R. J. (2011) Heart attack stopping gene spurs biotech race. Bloomberg, November 11.
61. Cannon, C. P. (2011) High-density lipoprotein cholesterol as the Holy Grail. Journal of the American Medical Association, 306, 2153-2155.
62. Inazu, A., Brown, M. L., Hesler, C. B., Agellon, L. B., Koizumi, J., Takata, K., Maruhama, Y., Mabuchi, H., Tall, A. R., (1990) Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. New England Journal of Medicine, 323, 1234-1238.
63. Barter, P. J., Caufield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca L., Tarde, J. C., Waters, D. D., Shear, C. L., Revkin, J. H., Buhr, K. A., Fisher, M. R., Tall, A. R., Brewer, B. (2007) Effects of torcetrapib in patients at high risk for coronary events. New England Journal of Medicine, 357, 2109-2122.
64. Danaei, G., Finucane, M. M., Lu, Y., Singh, G. M., Conan, M. J., Paciorek, C. J., Lin, J. K., Farzadfar, F., Khang, Y.-M., Stevens, G. A., Rao, M., Ali, M. K., Riley, L. M., Robinson, C. A., Ezzati, M. (2011) National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: Systemic analysis of health examination survey and epidemiological studies with 370 countryyears and 2.7 million participants. The Lancet, DOI: 10.1016/50140-6736 (11) 60679-X.
65. Naik, G. (2011) Diabetes cases double to 347 million. Wall Street Journal, June 27.
66. Pollack, A. (2011) Novel diabetes drug is rejected by an FDA panel. New York Times, July 20.
67. Fauci, A. S., Morens, D. M. (2012) The perpetual challenge of infectious diseases. New England Journal of Medicine, 366, 454-461.
68. Laurence, J. (2012) Experts fear diseases "impossible to treat." The Independent, February 20.
69. Timmerman, L. (2012) Optimer, following Pfizer's playbook, has big plans for antibiotic. www. xconomy.com, January 31.
70. Yukhananov, A. (2012) Groups asks FDA to treat superbugs like rare diseases. Reuters, March 7.
71. Petersen, M. (2008) A bitter pill for Big Pharma. Los Angeles Times, January 27.
72. Armstrong, D. (2011) Pfizer after Lipitor slims down to push mini-blockbusters. Bloomberg, November 30.
73. Rockoff, J. (2011) Pfizer's future: A niche blockbuster. Wall Street Journal, August 30.
74. Ledford, H. (2012) Success through cooperation. Nature News, February 1.
75. Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., Schacht, A. L. (2010) How to improve R&D productivity: The pharmaceutical industry's grand challenge. Nature Reviews Drug Discovery, 9, 203-214.
76. Herper, M. (2011) Serial lifesaver. Forbes, September 26.
77. Barber, S. (2007) Celgene: The pharmaceutical Phoenix. Chemical Heritage Newsmagazine, 24, 1-2.
78. Marcus, A. D. (2011) Researchers show gains in finding reusable drugs. Wall Street Journal, August 18.
79. Oprea, T. I., Bauman, J. E., Bologa, C. G., Buranda, T., Chigaev, A., Edwards, B. S., Jarvik, J. W., Gresham, H. D., Haynes, M. K., Hjelle, B., Hromas, R., Hudson, L., Markenzie, D. A., Muller, C. Y., Reed, J. C., Simons, P. C., Smagley, Y., Strouse, J., Surviladze, Z, Thompson, T., Ursu, O., Waller, A., Wandinger-Ness, A., Winter, S. S., Wu, Y., Young, S. M., Larson, R. S., Wilman, C., Sklar, L. A. (2011) Drug repurposing from an academic perspective. Drug Discovery Today: Therapeutic Strategies, 8, 61-69.
80. Gottlieb, S. (2011) Big Pharma's new business model. Drug makers aren't chasing blockbusters like Lipitor anymore, or uncovering compounds in the same way. Wall Street Journal, December 27.
81. Scannell, J. W., Blanckley, A., Boldon, H., Warrington, B. (2012) Diagnosing the decline in pharmaceutical R&D efficiency. Nature Reviews Drug Discovery, 11, 191-200.
82. McCarron, R., Banks, M. N., Bojanic, D., Burns, D. J., Cirovic, D. A., Garyantes, T., Green, D. V. S., Hertzberg, R. P., Janzen, W. P., Paslay, J. W., Schopfer, U., Sittampalam, G. S. (2011) Impact of high-throughput screening in biomedical research. Nature Reviews Drug Discovery, 10, 188-195.
83. Schumpeter (2011) Big and clever-Why large firms are more inventive than small ones. The Economist, December 17.
84. Timmerman, L. (2011) The fall of Pfizer: How big is too big for Pharma innovation. Xconomy, August 29.
85. Stovall, S. (2012) To outsource or not to outsource? That's the Pharma R&D question. Wall Street Journal, The Source Blog, February 7.
86. Timmerman, L. (2012) Xconomist of the week: Roger Perlmutter's parting thoughts on Amgen, Xconomy, March 1.
87. Bloom, J., Torreele, E. (2012) Should patents on pharmaceuticals be extended to encourage innovation? Wall Street Journal, January 23.
88. Goldstein, K., Doorley, J. (2011) Corporate reputation management in the U.S. pharmaceutical industry. Institute for Public Relations. www.instituteforpr.org.
89. Kennedy, K. (2012) Drugmakers have paid $8 billion in fraud fines. USA Today, March 5.
90. Wilson, D. (2010) When the side effects may include lawsuits. New York Times, October 3.
91. Brody, H. (2012) Opinion: Celebrities pushing drugs? Celebrity spokespeople for pharma companies can manipulate the public's understanding of disease. The Scientist, January 30 http://thescientist. com/daily/2012/01/31a.htm.
92. Rosenthal, E. (2012) I Disclose... Nothing. New York Times, January 22.
93. Silverman, E. (2012) Waiting For Godot: Merck The FDA And Post-Marketing Studies That Never Arrive http://www.forbes.com/edsilverman/2012/02/29/
94. Doshi, P., Jefferson, T. (2012) Drug data shouldn't be secret. New York Times, April 10.
95. Pear, R. (2012) U.S. to force drug firms to report money paid to doctors. New York Times, January 12.
96. Melnikova, I., (2012) Rare Diseases and Orphan Drugs. Nature Reviews Drug Discovery, 11, 267-268.
97. www.ifpma.org/healthpartnerships
98. Smith, J. (2010) America's most generous companies. Forbes.com, October 28.
99. Herper, M. (2012) The Gardisil problem: How the U.S. lost faith in a promising vaccine. Forbes, April 23.
100. Rockoff, J. D., Winslow, R. (2011) Drug Makers Refill Parched Pipelines. Wall Street Journal, July 11.
101. Rockoff, J. D. (2011) Pfizer, Merck Take Different R&D Tacks. Wall Street Journal, February 4.
102. Todd, S. (2011) Merck CEO Frazier stresses innovation will be key to drug makers' success. The Star Ledger, May 24.
103. Pierson, R. (2011) Lilly CEO defends R&D spending. Reuters, June 30.